secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0000950170-22-008734
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid reports Q1 net loss $16.1M, revenue $1.4M; OV329 IND on track for Q4 2022
------------------------------------------------------------------------------

- Net loss $16.1M ($0.23/sh) vs net income $176M in Q1 2021 on one-time Takeda payment.
- Revenue fell to $1.4M from $208.4M; current revenue from Marinus and Healx license fees.
- Cash and equivalents $166.7M expected to fund pipeline into 2025.
- IND for OV329 (GABA aminotransferase inhibitor) planned in Q4 2022 to start Phase 1.
- Non-GAAP adjusted operating expenses were $14.2M; total operating expenses $17.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000095017022008734/0000950170-22-008734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000095017022008734/ovid-20220510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer